PEDIATRICS Vol. 63 No. 2 February 1979, pp. 198-203
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beem, M. O.
Right arrow Articles by Tipple, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beem, M. O.
Right arrow Articles by Tipple, M. A.

Treatment of Chlamydial Pneumonia of Infancy

Marc O. Beem M.D.1, Evelyn Saxon B.S.1, and Margaret A. Tipple M.D.1

1 Department of Pediatrics, University of Chicago, Chicago

Infants with untreated chlamydial pneumonia shed Chlamydia trachomatis and are symptomatic for many weeks. We used sulfisoxazole, 150 mg/kg/day, or erythromycin ethyl succinate, 40 mg/kg/day, for approximately 14 days to treat 32 patients with chlamydial pneumonia of infancy, and observed them for nasopharyngeal shedding of C trachomatis and changing clinical status. All infants stopped shedding chlamydiae soon after treatment was started. After treatment, three of the 25 infants tested again became culture positive (but did not have clinical relapse). All infants improved clinically. In 24 (83%) of 29 infants, where the onset of improvement could be timed, improvement began within seven days of starting treatment. Progression to complete recovery was observed in 27 of 28 infants examined between two weeks and two months of treatment completion. Neither the existence of concomitant viral infection nor the duration of illness or hospitalization before starting treatment influenced the interval between initiation of treatment and onset of clinical improvement. While these observations do not prove, they are at least compatible with the hypotheses that C trachomatis plays a central etiologic role in this illness and that termination of chlamydial infection is beneficial clinically. Pending the availibility of data from controlled studies, we believe that either of the treatment programs outlined warrant consideration in the clinical management of patients with chlamydial pneumonia of infancy.

Submitted on April 6, 1978
Accepted on June 21, 1978




This article has been cited by other articles:


Home page
 J. Immunol.Home page
M. Jupelli, M. N. Guentzel, P. A. Meier, G. Zhong, A. K. Murthy, and B. P. Arulanandam
Endogenous IFN-{gamma} Production Is Induced and Required for Protective Immunity against Pulmonary Chlamydial Infection in Neonatal Mice
J. Immunol., March 15, 2008; 180(6): 4148 - 4155.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
G. Mundel, I. Katz, G. Eshel, and D. Sompolinsky
Superinfection of Chlamydia trachomatis Pneumonia by Staphylococcus aureus
Clinical Pediatrics, August 1, 1982; 21(8): 499 - 501.
[PDF]

Home page
 CLIN PEDIATRHome page
V. H. San Joaquin, J. R. Herrin, and J. M. Hautala
Chlamydial Pneumonia of Infancy: Further Clinical Observations
Clinical Pediatrics, February 1, 1980; 19(2): 109 - 112.
[Abstract] [PDF]